{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-017916","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.181760+00:00","generated_at":"2026-05-17T03:59:37.009000+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir Pharma reports Telomir-1 kills pancreatic cancer cells in vitro; plans further studies","bullets":["Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in concentration-dependent manner.","Effects partially reversed by iron re-addition, suggesting iron-dependent processes contribute to response.","Telomir-1 previously shown to influence tumor suppressor genes and iron-dependent histone demethylases relevant to pancreatic cancer.","Pancreatic cancer has five-year survival rate of ~12%; current treatments limited by toxicity and resistance.","Telomir plans to expand preclinical research to leukemia models and initiate in vivo validation studies for IND preparation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-017916","json":"https://secwatch.observer/filing/0001493152-25-017916.json","markdown":"https://secwatch.observer/filing/0001493152-25-017916.md","text":"https://secwatch.observer/filing/0001493152-25-017916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225017916/0001493152-25-017916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225017916/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:59:37.009000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}